Gallbladder hemorrhage during orally administered edoxaban therapy: a case report

Abstract Background Edoxaban is an orally administered anticoagulant treatment that is used in patients with cerebral infarction, venous thrombosis, or other conditions, with a reported incidence of gastrointestinal hemorrhage at approximately 1%. We encountered the rare case of a patient who develo...

Full description

Bibliographic Details
Main Authors: Hideya Itagaki, Suzuki Katuhiko
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Journal of Medical Case Reports
Subjects:
Online Access:https://doi.org/10.1186/s13256-019-2328-9
id doaj-5df24e543e544c4792dbf63ae948a150
record_format Article
spelling doaj-5df24e543e544c4792dbf63ae948a1502020-12-27T12:06:19ZengBMCJournal of Medical Case Reports1752-19472019-12-011311410.1186/s13256-019-2328-9Gallbladder hemorrhage during orally administered edoxaban therapy: a case reportHideya Itagaki0Suzuki Katuhiko1Department of General Surgery, Honjou Daiichi HospitalDepartment of General Surgery, Honjou Daiichi HospitalAbstract Background Edoxaban is an orally administered anticoagulant treatment that is used in patients with cerebral infarction, venous thrombosis, or other conditions, with a reported incidence of gastrointestinal hemorrhage at approximately 1%. We encountered the rare case of a patient who developed a gallbladder hemorrhage after the administration of edoxaban. Case presentation An 86-year-old Japanese woman visited our gastrointestinal department due to the chief complaint of melena lasting for a week. Her medical history included hypertension and embolic cerebral infarction, and she was taking orally administered carvedilol (5 mg/day) and edoxaban (30 mg/day). Her palpebral conjunctiva was pale during a physical examination, indicating the possibility of anemia. Her blood test results confirmed severe anemia with red blood cells at 1.7 × 106/μL and hemoglobin at 4.7 g/dL. An upper gastrointestinal endoscopy revealed bile and fresh blood on the duodenal bulb and in more distal regions; hemobilia was suspected. A computed tomography scan on the ninth hospitalization day confirmed the hemobilia with a gallbladder fundus high-density signal. She was discharged on the 30th day of hospitalization with only fluid therapy and no progression of anemia. Moreover, she underwent a laparoscopic cholecystectomy 1 month after discharge, but the pathologist did not identify false aneurysms or neoplastic lesions. She has not been shown to develop anemia for 5 months after surgery. Conclusions Our case suggests that gallbladder hemorrhage needs to be considered a possible complication for patients on direct oral anticoagulants.https://doi.org/10.1186/s13256-019-2328-9Direct oral anticoagulant (DOAC)EdoxabanGallbladder hemorrhageHemobiliaUpper gastrointestinal hemorrhage
collection DOAJ
language English
format Article
sources DOAJ
author Hideya Itagaki
Suzuki Katuhiko
spellingShingle Hideya Itagaki
Suzuki Katuhiko
Gallbladder hemorrhage during orally administered edoxaban therapy: a case report
Journal of Medical Case Reports
Direct oral anticoagulant (DOAC)
Edoxaban
Gallbladder hemorrhage
Hemobilia
Upper gastrointestinal hemorrhage
author_facet Hideya Itagaki
Suzuki Katuhiko
author_sort Hideya Itagaki
title Gallbladder hemorrhage during orally administered edoxaban therapy: a case report
title_short Gallbladder hemorrhage during orally administered edoxaban therapy: a case report
title_full Gallbladder hemorrhage during orally administered edoxaban therapy: a case report
title_fullStr Gallbladder hemorrhage during orally administered edoxaban therapy: a case report
title_full_unstemmed Gallbladder hemorrhage during orally administered edoxaban therapy: a case report
title_sort gallbladder hemorrhage during orally administered edoxaban therapy: a case report
publisher BMC
series Journal of Medical Case Reports
issn 1752-1947
publishDate 2019-12-01
description Abstract Background Edoxaban is an orally administered anticoagulant treatment that is used in patients with cerebral infarction, venous thrombosis, or other conditions, with a reported incidence of gastrointestinal hemorrhage at approximately 1%. We encountered the rare case of a patient who developed a gallbladder hemorrhage after the administration of edoxaban. Case presentation An 86-year-old Japanese woman visited our gastrointestinal department due to the chief complaint of melena lasting for a week. Her medical history included hypertension and embolic cerebral infarction, and she was taking orally administered carvedilol (5 mg/day) and edoxaban (30 mg/day). Her palpebral conjunctiva was pale during a physical examination, indicating the possibility of anemia. Her blood test results confirmed severe anemia with red blood cells at 1.7 × 106/μL and hemoglobin at 4.7 g/dL. An upper gastrointestinal endoscopy revealed bile and fresh blood on the duodenal bulb and in more distal regions; hemobilia was suspected. A computed tomography scan on the ninth hospitalization day confirmed the hemobilia with a gallbladder fundus high-density signal. She was discharged on the 30th day of hospitalization with only fluid therapy and no progression of anemia. Moreover, she underwent a laparoscopic cholecystectomy 1 month after discharge, but the pathologist did not identify false aneurysms or neoplastic lesions. She has not been shown to develop anemia for 5 months after surgery. Conclusions Our case suggests that gallbladder hemorrhage needs to be considered a possible complication for patients on direct oral anticoagulants.
topic Direct oral anticoagulant (DOAC)
Edoxaban
Gallbladder hemorrhage
Hemobilia
Upper gastrointestinal hemorrhage
url https://doi.org/10.1186/s13256-019-2328-9
work_keys_str_mv AT hideyaitagaki gallbladderhemorrhageduringorallyadministerededoxabantherapyacasereport
AT suzukikatuhiko gallbladderhemorrhageduringorallyadministerededoxabantherapyacasereport
_version_ 1724369386676944896